Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides

Nucleic Acids Research

Volumn 33, Issue 13, 2005, Pages 4345-4356

  Tripathi, Snehlata ^a   Chaubey, Binay ^a   Ganguly, Sabyasachi ^a   Harris, Dylan ^a   Casale, Ralph A ^b   Pandey, Virendra N ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Applied Biosystems Framingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NUCLEIC ACID; POLYAMIDE NUCLEIC ACID PENETRATIN CONJUGATE; POLYAMIDE NUCLEIC ACID TRANSACTIVATOR PROTEIN CONJUGATE; POLYAMIDE NUCLEIC ACID TRANSPORTAN 21 CONJUGATE; POLYAMIDE NUCLEIC ACID TRANSPORTAN 22 CONJUGATE; POLYAMIDE NUCLEIC ACID TRANSPORTAN 27 CONJUGATE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HIV 1 TAT PROTEIN (48 60); HIV-1 TAT PROTEIN (48-60); HOMEODOMAIN PROTEIN; HYBRID PROTEIN; NUCLEOTIDE; PENETRATIN (43 58), HUMAN; PENETRATIN (43-58), HUMAN; PEPTIDE; PEPTIDE FRAGMENT; PEPTIDE NUCLEIC ACID; TRANSACTIVATOR PROTEIN; VIRUS DNA;

5' UNTRANSLATED REGION; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DRUG TARGETING; FLUORESCENCE ACTIVATED CELL SORTING; GENE TARGETING; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN RNA BINDING; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; CELL CULTURE; CELL MEMBRANE; CHEMISTRY; DRUG EFFECT; KINETICS; LONG TERMINAL REPEAT; METABOLISM; NUCLEIC ACID PROBE; REVERSE TRANSCRIPTION; TRANSPORT AT THE CELLULAR LEVEL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; ANTISENSE ELEMENTS (GENETICS); BIOLOGICAL TRANSPORT; CELL MEMBRANE; CELLS, CULTURED; DNA, VIRAL; GENE PRODUCTS, TAT; HIV LONG TERMINAL REPEAT; HIV-1; HOMEODOMAIN PROTEINS; KINETICS; NUCLEIC ACIDS; NUCLEOTIDES; PEPTIDE FRAGMENTS; PEPTIDE NUCLEIC ACIDS; PEPTIDES; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTION; VIRUS REPLICATION;

EID: 23844510658     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gki743     Document Type: Article

References (52)

1. Kress,K.D. (2004) HIV update: Emerging clinical evidence and a review of recommendations for the use of highly active antiretroviral therapy. Am. J. Health Syst. Pharm., 61, S3-S14.
2. Merson,M.H. (1993) Slowing the spread of HIV: Agenda for the 1990s. Science, 260, 1266-1268.
3. Ketas,T.J., Klasse,P.J., Spenlehauer,C., Nesin,M., Frank,I., Pope,M., Strizki,J.M., Reyes,G.R., Baroudy,B.M. and Moore,J.P. (2003) Entry inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 replication in multiple cell types. AIDS Res. Hum. Retroviruses, 19, 177-186.
4. Borkow,G., Salomon,H., Wainberg,M.A. and Parniak,M.A. (2002) Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding non-nucleoside reverse transcriptase inhibitor. AIDS Res. Hum. Retroviruses, 18, 711-714.
5. Creagh,T., Ruckle,J.L., Tolbert,D.T., Giltner,J., Eiznhamer,D.A., Dutta,B., Flavin,M.T. and Xu,Z.Q. (2001) Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring non-nucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother., 45, 1379-1386.
6. Piret,J., Lamontagne,J., Bestman-Smith,J., Roy,S., Gourde,P., Désormeaux,A., Omar,R.F., Juhász,J. and Bergeron,M.G. (2000) In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses. J. Clin. Microbiol., 38, 110-119.
7. Muesing,M.A., Smith,D.H. and Capon,D.J. (1987) Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell, 48, 691-701.
8. Ratner,L., Haseltine,W., Patarca,R., Livak,K.J., Starcich,B., Josephs,S.F., Doran,E.R., Rafalski,J.A., Whitehorn,E.A., Baumeister,K. et al. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature, 313, 277-284.
9. Sherman,P.A., Dickson,M.L. and Fyfe,J.A. (1992) Human-immunodeficiency virus type 1 integration protein: DNA sequence requirements for cleaving and joining reactions. J. Virol., 66, 3593-3601.
10. Wakefield,J.K., Kang,S. and Morrow,C.D. (1996) Construction of a type 1 human immunodeficiency virus that maintains a primer-binding site complementary to tRNA (His). J. Virol., 70, 966-975.
11. Vink,C., VanGent,D.C., Elgersma,Y. and Plasterk,R.H.A. (1991) Human immunodeficiency virus integrase protein requires a sub-terminal position of its viral DNA recognition sequence for efficient cleavage. J. Virol., 65, 4636-4644.
12. Cullen,B.R. and Greene,W.C. (1990) Functions of the auxiliary gene products of the human immunodeficiency virus type 1. Virology, 178, 1-5.
13. Feng,S. and Holland,E.C. (1988) HIV-1 Tat trans-activation requires the loop sequence within TAR. Nature, 334, 165-167.
14. Harrich,D., Ulich, C., Garcia-Martinez,L.F. and Gaynor, R.B. (1997) Tat is required for efficient HIV-1 reverse transcription. EMBO J., 16, 1224-1235.
15. Kurreck,J. (2003) Antisense technologies. Eur. J. Biochem., 270, 1628-1644.
16. Crooke,S.T. (2004) Progress in antisense technology. Ann. Rev. Med., 55, 61-95.
17. Neilsen,P.E., Egholm,M., Berg,R.H. and Buchardt,O. (1991) Sequence-selective recognition of DNA by strand displacement with a thymidine-substituted polyamide. Science, 254, 1497-1500.
18. Lee,R., Kaushik,N., Modak,M.J., Vinayak,R. and Pandey,V.N. (1998) Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription. Biochemistry, 37, 900-910.
19. Lys in the virions and inhibits HIV-1 replication. Virology, 303, 297-308.
20. Lys from the primer-binding site of HIV-1 genome by anti-A loop polyamide nucleotide analog. Nucleic Acids Res., 29, 5099-5106.
21. Mayhood,T., Kaushik,N., Pandey,P.K., Kashanchi,F., Deng,L. and Pandey,V.N. (2000) Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Biochemistry, 39, 11532-11539.
22. Kaushik,N., Basu,A. and Pandey,V.N. (2002) Inhibition of HIV-1 replication by anti-trans-activation responsive polyamide nucleotide analog. Antiviral Res., 56, 13-27.
23. Kaushik,N., Basu,A., Palumbo,P., Myers,R.L. and Pandey,V.N. (2002) Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J. Virol., 76, 3881-3891.
24. Chaubey,B., Tripathi,S., Ganguly,S., Harris,D., Casale,R.A. and Pandey,V.N. (2005) A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties. Virology, 331, 418-428.
25. Derossi,D., Calvet,S., Trembleau,A., Brunissen,A., Chassaing,G. and Prochiantz,A. (1996) Cell internalization of the third helix of the antennapedia homeodomain is receptor-independent. J. Biol. Chem., 271, 18188-18193.
26. Derossi,D., Chassaing,G. and Prochiantz,A. (1998) Trojan peptides: The penetratin system for intracellular delivery. Trends Cell Biol., 8, 84-87.
27. Schwarze,S.R., Ho,A., Vocero-Akbani,A. and Dowdy,S.F. (1999) In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science, 285, 1569-1572.
28. Soomets,U., Lindgren,M., Gallet,X., Hällbrink,M., Elmquist,A., Balaspiri,L., Zorko,M., Pooga,M., Brasseur,R. and Langel,Ü. (2000) Deletion analogues of transportan. Biochim. Biophys. Acta., 1467, 165-176.
29. Bernatowicz,M.S., Matsueda,R. and Matsueda,G.R. (1986) Preparation of Boc-[S-(3-nitro-2-pyridinesulfenyl)]-cysteine and its use for unsymmetrical disulfide bond formation. Int. J. Pept. Protein Res., 28, 107-112.
30. Gunnery,S., Green,S.R. and Mathews,M.B. (1992) Tat-responsive region RNA of human immunodeficiency virus type 1 stimulates protein synthesis in vivo and in vitro: Relationship between structure and function. Proc. Natl Acad. Sci. USA, 89, 11557-11561.
31. Sanger,F., Nicklen,S. and Coulson,A.R. (1977) DNA sequencing with chain terminating inhibitors. Proc. Natl Acad. Sci. USA, 74, 5463-5467.
32. Kashanchi,F., Shibata,R., Ross,E.K., Brady,J.N. and Martin,M.A. (1994) Second-site long terminal repeat (LTR) revertants of replication-defective human immunodeficiency virus: Effects of revertant TATA box motifs on virus infectivity, LTR-directed expression, in vitro RNA synthesis and binding of basal transcription factors TFIID and TFIIA. J. Virol., 68, 3298-3307.
33. Planelles,V., Bachelerie,F., Jowett,J.B., Haislip,A., Xie,Y., Banooni,P., Masuda,T. and Chen,I.S. (1995) Fate of the human immunodeficiency virus type 1 provirus in infected cells: A role for vpr. J. Virol., 69, 5883-5889.
34. Chou,T.-C. (1974) Relationships between inhibition constants and fractional inhibitions in enzyme-catalysed reations with different numbers of reactants, different reaction mechanisms, and different types of mechanisms of inhibition. Mol. Pharmacol., 39, 235-247.
35. Chou,T.-C. (1977) Derivation and properties of Michaelis-Menten type and Hill equations for reference ligands. J. Theoret. Biol., 39, 345-356.
36. Vivès,E., Brodin,P. and Lebleu,B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem., 272, 16010-16017.
37. Pooga,M., Hällbrink,M., Zorko,M. and Langel,Ü. (1998) Cell penetration by transportan. FASEB, 12, 67-77.
38. Dom,G., Shaw-Jackson,C., Matis,C., Bouffioux,O., Picard,J.J., Prochiantz,A., Mingeot-Leclereq,M., Brasseur,R. and Rezsohazy,R. (2003) Cellular uptake of Antennapedia penetratin peptides is a two-step process in which phase transfer precedes a tryptophan-dependent translocation. Nucleic Acids Res., 31, 556-561.
39. Estcourt,M.J., McMichael,A.J. and Hanke,T. (2004) DNA vaccine against human immunodeficiency virus type 1. Immunol. rev., 199, 144-155.
40. Buchardt,O., Egholm,M., Berg,R.H. and Nielsen,P.E. (1993) Peptide nucleic acids and their potential applications in biotechnology. Trends Biotechnol., 11, 384-386.
41. Marin,V.L., Roy,S. and Armitage,B.A. (2004) Recent advances in the development of peptide nucleic acid as a gene-targeted drug. Expert Opin. Biol. Ther., 4, 337-348.
42. Koppelhus,U. and Nielsen,P.E. (2003) Cellular delivery of peptide nucleic acid (PNA). Adv. Drug Delivery Rev., 55, 267-280.
43. Taylor,R.W., Chinnery,P.F., Turnbull,D.M. and Lightowlers,R.N. (1997) Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nature Genet., 15, 212-215.
44. Shammas,M.A., Simmons,C.G., Corey,D.R. and ShmooklerReis,R.J. (1999) Telomerase inhibition by PNA reverses 'immortality' of transformed human cells. Oncogene, 18, 6191-6200.
45. Herbert,B.-S., Pitts,A.E., Baker,S.I., Hamilton,S.E., Wright,W.E., Shay,J.W. and Corey,D.R. (1999) Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl Acad. Sci. USA, 96, 14276-14281.
46. Nulf,C.J. and Corey,D. (2004) Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES)-dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs). Nucleic Acids Res., 32, 3792-379847.
47. Richard,J.P., Melikov,K., Vives,E., Ramos,C., Verbeure,B., Gait,M.J., Chernomordik,L.V. and Lebleu,B. (2003) Cell-penetrating peptides. J. Biol. Chem., 278, 585-590.
48. Richard,J.P., Melikov,K., Brooks,H., Prevot,P., Lebleu,B. and Chernomordik,L.V. (2005) Cellular uptake of unconjugated tat-peptide involves clathrin dependent endocytosis and heparan sulfate receptors. J. Biol. Chem., 280, 15300-15306.
49. Wadia,J.S., Stan,R.V. and Dowdy,S.F. (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nature Medicine, 10, 310-315.
50. Wild,C., Greenwell,T. and Matthews,T. (1993) A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses, 9, 1051-1053.
51. Derdeyn,C.A., Decker,J.M., Sfakianos,J.N., Wu,X., O'Brien,W.A., Ratner,L., Kappes,J.C., Shaw,G.M. and Hunter,E. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol., 74, 8358-8367.
52. Nagashima,K.A., Thompson,D.A., Rosenfield,S.I., Maddon,P.J., Dragic,T. and Olson,W.C. (2001) Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis., 183, 1121-1125.